Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | SORD | Q00796 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 2/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | CCR8 | P51685 | 2/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22958644 | 0.82 | GRM4 (0.35) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL28402863 | 0.82 | GRM4 (0.35) | GRM4KDM4ELMNANOS3NOS1 | |
| SCHEMBL21323650 | 0.82 | GRM4 (0.35) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL31728162 | 0.82 | SORD (0.36) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL24359772 | 0.80 | GRM4 (0.34) | GRM4KDM4ELMNANOS3NOS2 | |
| SCHEMBL23206269 | 0.79 | IDH1 (0.36) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL28223078 | 0.79 | POLB (0.40) | GRM4KDM4ELMNAPOLBAAK1 | |
| SCHEMBL25986793 | 0.77 | GRM4 (0.33) | GRM4KDM4ELMNA | |
| SCHEMBL1106508 | 0.76 | HRH4 (0.38) | CHRNA7NOS3NOS1NOS2POLB | |
| SCHEMBL21784412 | 0.76 | GRM4 (0.34) | GRM4KDM4ELMNANOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STINGINN INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024133721-A1 | COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138206-A1 | FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133730-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7368473-B2 | Paclitaxel enhancer compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070244138-A1 | Mercaptoimidazoles as Ccr2 Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244138-A1 | Mercaptoimidazoles as Ccr2 Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | GRM4 824/4885CHRNA7 1007/4885KDM4E 4298/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GRM4 2784/4885CHRNA7 4869/4885KDM4E 3314/4885 |
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STING1, IRF3, MAVS | GRM4 3655/4885CHRNA7 4214/4885KDM4E 2288/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | GRM4 4736/4885CHRNA7 4161/4885KDM4E 796/4885 |
| US-20070244138-A1 | Mercaptoimidazoles as Ccr2 Receptor Antagonists | CCR2, CCR1, CCR5 | GRM4 771/4885CHRNA7 286/4885KDM4E 3486/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | GRM4 3917/4885CHRNA7 4652/4885KDM4E 1830/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GRM4 2784/4885CHRNA7 4869/4885KDM4E 3314/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | GRM4 1581/4885CHRNA7 2265/4885KDM4E 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.